Ally Bridge Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ally Bridge Group’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-70,283	Closed	-$3.06M	–	26
2023 Q3	$3.06M	Buy	+70,283	New	+$2.51M	3.59%	12
2023 Q1	–	Sell	-47,520	Closed	-$2.15M	–	42
2022 Q4	$2.15M	Buy	+47,520	New	+$3.08M	2.09%	20
2022 Q1	–	Sell	-85,000	Closed	-$12.5M	–	31
2021 Q4	$12.5M	Sell	85,000 -10,000	-11%	-$1.55M	4.36%	7
2021 Q3	$16.8M	Hold	95,000	–	–	4.94%	5
2021 Q2	$15.3M	Buy	+95,000	New	+$15.3M	3.81%	12

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Ally Bridge Group's MRTX Position: Q4 2023 in Review

Ally Bridge Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 70,283 shares — an estimated $3.06M sold.

Ally Bridge Group first reported a position in MRTX in Q2 2021 and held it in 5 quarters. The position peaked at $16.8M in Q3 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Ally Bridge Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Ally Bridge Group sold 70,283 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.06M.
Ally Bridge Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Ally Bridge Group's Mirati Therapeutics, Inc. Common Stock position peaked at $16.8M in Q3 2021.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Ally Bridge Group's 13F filing for Q4 2023, filed 14 Feb 2024.